Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Interferon beta-1a may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
What AVONEX is The active substance in Avonex is a protein called interferon beta-1a. Interferons are natural substances made in your body to help protect you from infections and diseases. The protein in Avonex is made up of exactly the same ingredients as interferon beta that is found in the human body. What AVONEX is used for Avonex is used to treat Multiple Sclerosis (MS). Treatment with Avonex can help to prevent you from getting worse, although it will not cure MS. Everyone has their own set of MS symptoms. These can include: Feeling off-balance or light headed, walking problems, stiffness and muscle spasms, tiredness, numbness in the face, arms or legs Acute or chronic pain, bladder and bowel problems, sexual problems and problems seeing things
Difficulty in thinking and concentrating, depression. MS also tends to flare up from time to time: this is called a relapse. (Notes information) Avonex works best when you use it: at the same time once a week on a regular basis Do not stop your Avonex treatment without speaking to your doctor. Avonex can help to reduce the number of relapses that you have and slow down the disabling effects of MS. Your doctor will advise you for how long you can use Avonex or when to stop. How AVONEX works Multiple sclerosis is linked to nerve (brain or spinal cord) damage. In MS, your body's defence system reacts against its own myelin – the 'insulation' that surrounds nerve fibres. When myelin is damaged, the messages between the brain and other parts of the body are disrupted. This is what causes the symptoms of MS. Avonex seems to work by stopping your body's defence system from attacking the myelin. 2.
e AVONEX
Do not use AVONEX –
If you are allergic to interferon beta or any of the other ingredients of this medicine (listed in section 6) If you have severe depression or think about committing suicide.
Talk to a doctor straight away if any of these apply to you. (Notes information) Avonex and allergic reactions. Because Avonex is based on a protein, there is a small chance of an allergic reaction. More about depression. If you have severe depression or thoughts about suicide, you must not use Avonex. If you have depression, your doctor may still prescribe Avonex for you, but it's important to let your doctor know if you have had depression or any similar problems affecting your moods.
Warnings and precautions Talk to your doctor before using Avonex if you have or have had in the past: Depression or problems affecting your moods Thoughts about committing suicide.
Changes to your mood, thoughts about suicide, feeling unusually sad, anxious or worthless, should be reported to your doctor immediately. Epilepsy or other seizure disorders not controlled by medication Serious kidney or liver problems A low number of white blood cells or platelets, which can cause an increased risk of infection, bleeding or anaemia Heart problems, which can cause symptoms such as chest pain (angina), particularly after any activity; swollen ankles, shortness of breath (congestive heart failure); or an irregular heartbeat (arrhythmias). Irritation at an injection site, which can lead to skin and tissue damage (injection site necrosis). When you are ready to inject, carefully follow the instructions in section 7 "How to inject AVONEX", at the end of this leaflet. This is to reduce the risk of injection site reactions. Talk to your doctor if you have any of these conditions, or if they worsen whilst taking Avonex. Blood clots in the small blood vessels may occur during your treatment. These blood clots could affect your kidneys. This might happen several weeks to several years after starting Avonex. Your doctor may want to check your blood pressure, blood (platelet count) and the function of your kidneys. Tell your doctor you are using Avonex: If you are having a blood test. Avonex may interfere with the results.
(Notes information) Sometimes you will need to remind other medical staff that you are being treated with Avonex. For example, if you are prescribed other medicines, or if you have a blood test, Avonex may affect the other medicines or the test result.
Paediatric population Avonex is not recommended for use in children and adolescents because there is limited data on the use of Avonex in this population. Avonex should not be used in children below 10 years of age because it is yet to be established whether it would work for them and whether it would be safe. Other medicines and AVONEX Tell your doctor if you are using, have recently used or might use any other medicines, especially those used to treat epilepsy or depression. Avonex may affect other medicines or be affected by them. This includes any other medicines including medicines obtained without a prescription. Pregnancy and breast-feeding If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
No harmful effects on the breastfed newborn/infant are anticipated. Avonex can be used during breastfeeding. Driving and using machines If you feel dizzy, do not drive. Avonex makes some people feel dizzy. If this happens to you, or if you get any other side effects that could affect your ability, do not drive or use machines. Important information about some of the ingredients of AVONEX This medicine is essentially 'sodium-free'. It contains less than 23 mg (1 mmol) sodium in each weekly dose. 3.
AVONEX
The recommended weekly dose One injection of Avonex, once a week. Try to use Avonex at the same time on the same day each week. If you have decided to start treatment with Avonex, your doctor may provide you with an Avostartclip titration kit. The Avostartclip attaches to the syringe and enables you to gradually increase your dose of Avonex when you first start treatment. This is to limit flu-like symptoms which some people experience when they start using Avonex. Your doctor or nurse will help you use the Avostartclip titration kit. (Notes information) Starting Avonex If you are new to Avonex, your doctor may advise you to gradually increase your dose so that you can adjust to the effects of Avonex before taking the full dose. You will be provided with an Avostartclip titration kit. Avostartclips can be attached onto the syringe enabling a reduced dose of Avonex to be injected at the start of treatment. Each Avostartclip should be used once and then discarded along with any remaining Avonex. For further details on use, speak with your doctor. Injecting yourself You can inject Avonex yourself without the help of your doctor, if they have trained you to do this. The instructions on how to inject yourself are at the end of this leaflet (see section 7, How to inject AVONEX). If you have trouble handling the syringe, ask your doctor who may be able to help. (Notes information) There are more details on how to inject Avonex at the end of this leaflet. Alternate needle:
Your pack of Avonex already includes a needle for injection. It may be possible for your doctor to prescribe you a shorter and thinner needle, depending on your body type. Talk to your doctor to see if this is appropriate for you. If you have problems handling the syringe, talk to your doctor about using a syringe grip. This is a specially designed holder to help you with injecting Avonex.
How long to use AVONEX Your doctor will tell you how long you need to keep using Avonex. It is important to continue using Avonex regularly. Do not make changes unless your doctor tells you. If you inject more than you should You should only have one injection of Avonex, once a week. If you have used more than one injection of Avonex in a three-day period, contact your doctor or pharmacist straight away for advice. If you miss an injection If you miss your usual weekly dose, inject a dose as soon as you can. Then leave a week before using Avonex again. Continue injecting on this new day every week. If you have a preferred day for using Avonex, talk to your doctor about managing the dose, to get back to your preferred day. Do not use two injections to make up for a missed injection. 4.
Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
(Notes information) Although the list of possible side effects can seem worrying, it's possible that you may not have any of them.
Serious side effects: get medical help Serious allergic reactions If you get any of these: Swelling of the face, lips or tongue Difficulty breathing A rash. Call a doctor immediately. Do not use any more Avonex until you have spoken to a doctor. Depression If you get any symptoms of depression: Feeling unusually sad, anxious or worthless.
Call a doctor immediately. Liver problems If you get any of these symptoms: Yellowing of your skin or the whites of your eyes (jaundice) Itching all over Feeling sick, being sick (nausea and vomiting) Easy bruising of the skin. Call a doctor immediately as they may be signs of a possible liver problem. Side effects seen in clinical trials (Notes information)
seen in clinical trials. These are the side effects that people reported when Avonex was being tested. The figures are based on how many people said they'd had them. It gives you an idea how likely you are to get similar side effects.
Very common side effects (may affect more than 1 in 10 people) Flu-like symptoms – headache, muscle aches, chills or a fever: see Flu-like symptoms, below Headache. Common side effects (may affect up to 1 in 10 people) Loss of appetite Feeling weak and tired Difficulty sleeping Depression Flushing Runny nose Diarrhoea (loose stools) Feeling or being sick (nausea or vomiting) Numbness or tingling of skin Rash, bruising of the skin Increased sweating, night sweats Pain in your muscles, joints, arms, legs or neck Muscle cramps, stiffness in the joints and muscles Pain, bruising and redness at the injection site Changes to blood tests. Symptoms you might notice are tiredness, repeated infection, unexplained bruising or bleeding. Uncommon side effects (may affect up to 1 in 100 people) Hair loss Changes to your monthly period Burning feeling at the site of injection.
Rare side effects (may affect up to 1 in 1,000 people) Difficulty breathing Kidney problems including scarring that may reduce your kidney function If you get some or all of these symptoms: Foamy urine Fatigue Swelling, particularly in the ankles and eyelids, and weight gain. Tell your doctor as they may be signs of a possible kidney problem. Blood clots in the small blood vessels that can affect your kidneys (thrombotic thrombocytopenic purpura or haemolytic uremic syndrome). Symptoms may include increased bruising, bleeding, fever, extreme weakness, headache, dizziness or light-headedness. Your doctor may find changes in your blood and the function of your kidneys. If any of the effects trouble you, talk to your doctor. Other side effects (Notes information) These effects have been seen in people using Avonex, but we do not know how likely they are to happen. If you feel dizzy, do not drive. –
An underactive or overactive thyroid Nervousness or anxiety, emotional instability, irrational thoughts or hallucinations (seeing or hearing things that are not real), confusion or suicide Numbness, dizziness, seizures or fits and migraines An awareness of your heartbeat (palpitations), a rapid or irregular heartbeat, or heart problems which would have the following symptoms: a reduced ability to exercise, inability to lie flat in bed, shortness of breath or swollen ankles Liver problems as described above Nettle rash or blister-like rash, itching, worsening of psoriasis if you have it Swelling or bleeding at the site of injection, tissue destruction (necrosis) or chest pain after an injection Gaining or losing weight Changes to test results, including changes to liver function tests Pulmonary arterial hypertension: A disease of severe narrowing of the blood vessels in the lungs resulting in high blood pressure in the blood vessels that carry blood from the heart to the lungs. Pulmonary arterial hypertension has been seen at various time points during treatment, including several years after starting treatment with interferon beta-products.
If any of the effects trouble you, talk to your doctor. Effects of the injection Feeling faint: Your first injection of Avonex may be given by your doctor. It may make you feel faint. You may even actually faint. This is unlikely to happen again.
–
Just after an injection, your muscles may feel tense or very weak – as though you are having a relapse. This is rare. It only happens when you inject and the effects soon pass. They may happen any time after starting on Avonex. If you notice any irritation or skin problems after an injection, talk to your doctor.
Flu-like symptoms (Notes information) Three simple ways to help reduce the impact of flu-like symptoms: 1. Use your Avonex injection just before bedtime. This may allow you to sleep through the effects. 2. Take paracetamol or ibuprofen half an hour before your Avonex injection and continue taking it for up to a day. Speak to your doctor or pharmacist about a suitable dose. 3. If you have a fever, drink plenty of water to keep you hydrated.
Some people find that after injecting Avonex, they feel like they have flu. Signs are: Headache Muscle aches Chills or a fever. These symptoms are not really flu You can't pass it on to anyone else. They are more common when you first start using Avonex. Your doctor may provide you with an Avostartclip titration kit which enables you to gradually increase your dose at the start of treatment to help limit flu-like symptoms. As you keep using your injections, the flulike symptoms gradually decrease. Children (10 years of age and above) and adolescents In clinical trials, some side effects were reported more frequently in children and adolescents than in adults, e.g., muscle pain, pain in extremity, fatigue, and joint pain. Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme. Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine. In order to improve the traceability of this medicine, your doctor or pharmacist should record the name and the lot number of the product you have been given in your patient file. You may also wish to make a note of these details in case you are asked for this information in the future.
5.
AVONEX
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date stated on the label. Store in the original package (sealed plastic tray) in order to protect from light. Store in a refrigerator (between 2°C and 8°C). Do not freeze. Avonex can also be stored at room temperature (between 15°C and 30°C) for up to one week. Do NOT use Avonex if you notice: The pre-filled syringe is broken. The sealed plastic tray is damaged or opened. The solution is coloured or you can see particles floating in it. The tamper evident cap has been broken. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6.
What AVONEX contains The active substance is: Interferon beta-1a 30 micrograms/0.5 ml The other ingredients are: Sodium acetate, trihydrate; acetic acid glacial, arginine hydrochloride, polysorbate 20 and water for injections. What AVONEX looks like and contents of the pack Avonex solution for injection comes as a ready to use injection In a box of Avonex there are four or twelve ready to use (pre-filled) syringes, each with 0.5 ml of a clear, colourless liquid inside. Not all pack sizes may be marketed. Each syringe is packed in a sealed plastic tray. A separate needle to give the injection is also included in the tray. Marketing Authorisation Holder and Manufacturer The Marketing Authorisation Holder is: Biogen Netherlands B.V. Prins Mauritslaan 13 1171 LP Badhoevedorp The Netherlands Avonex is made by: FUJIFILM Diosynth Biotechnologies Denmark ApS Biotek Allé 1, DK-3400 Hillerød, Denmark
Biogen Netherlands B.V. Prins Mauritslaan 13 1171 LP Badhoevedorp The Netherlands This leaflet was last revised in June 2023
7.
How to inject AVONEX
You should have had training in how to inject Avonex These notes are a reminder. If there's anything you're not sure about, check with your doctor or pharmacist. Where to inject
Avonex is injected into a muscle, for example, the upper thigh muscle. Injection of Avonex into the buttocks is not recommended. Use a different injection site each week. This means less risk of irritation to your skin and muscle. Do not use any area of skin that is bruised, sore, or infected, or if there is an open wound.
A. Getting Ready 1.
Remove one sealed plastic tray from the refrigerator Check the expiry date on the lid of the tray. Do not use it if it is out-of-date.
2.
Peel back the paper lid completely. Check the blister tray contains one pre-filled syringe and one injection needle (see picture "Contents of the plastic tray").
Leave the syringe to warm up Leave it at room temperature for half an hour. This makes the injection more comfortable than injecting straight from a refrigerator. Tip: Do not use external heat sources such as hot water to warm the syringe.
–
3.
Wash your hands thoroughly with soap and water and dry them.
4. Prepare alcohol wipes and sticking plasters (not supplied) if you need them. Find a clean, hard surface to lay out the items needed for your injection. Lay the tray down on it. B. Preparing the injection 1
Check the liquid in the syringe It should be clear and colourless. If the solution is cloudy, coloured or contains any floating particles, do not use the pre-filled syringe.
2
Remove the syringe cap The syringe has a white tamper-evident cap. Make sure the cap is intact and has not been opened. If it looks like it has been opened, do not use that syringe. Hold the syringe so that the white cap is facing up. Bend the cap at a right angle until it snaps off. Do not touch the connection port. Do not push on the plunger.
3
Fit the needle Open needle to expose the connection port. Keep the cover on. Press the needle onto the syringe. Turn it clockwise until it locks into place. Tip: Make sure the injection needle is firmly attached to the syringe. Otherwise it may leak. If you have been told to gradually increase your dose of Avonex, you may need to use an Avostartclip titration kit provided by your doctor. For further details, speak with your doctor Now pull off the plastic needle cover. Do not twist it. Tip: If you twist the needle cover to remove it, you may accidentally remove the needle as well.
C. Giving the injection 1
Clean and stretch the injection site If you need to, use an alcohol wipe to clean the skin at the injection site you've chosen. Allow the skin to dry. With one hand, stretch the skin around the injection site. Relax your muscle.
2
Make the injection Insert the injection needle with a quick dart-like thrust at right angles to the skin, into the muscle. The needle must go all the way in. Press the plunger slowly until the syringe is empty. If you are using a syringe that has an Avostartclip attached, you will receive a lower dose of Avonex. The syringe will not empty.
3
Pull the needle out Keep the skin stretched tightly or squeeze the skin around the injection site, and pull out the needle. If you use alcohol wipes, hold one on the injection site. Put a plaster over the site of injection if you need to. Dispose of the rubbish properly After you have finished each injection, put the needle and syringe into a special container (such as a sharps bin), not in ordinary rubbish. If you have used the Avostartclip, the syringe (and the Avostartclip) must be thrown away afterwards. The unused portion of Avonex must not be used. Waste paper and used wipes can be put in an ordinary rubbish bin.
AVONEX 30 micrograms/0.5 ml solution for injection comes as injection containing 30mcg / 0.5ml. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in AVONEX 30 micrograms/0.5 ml solution for injection is interferon beta-1a.
Medicines with the same active substance, strength and form include: AVONEX 30 micrograms/0.5ml solution for injection in pre-filled pen. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for AVONEX 30 micrograms/0.5 ml solution for injection, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
AVONEX is indicated in adults for the treatment of
• Patients diagnosed with relapsing multiple sclerosis (MS). In clinical trials, this was characterised by two or more acute exacerbations (relapses) in the previous three‑years without evidence of continuous progression between relapses; AVONEX slows the progression of disability and decreases the frequency of relapses.
• Patients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis (see section 5.1).
AVONEX should be discontinued in patients who develop progressive MS.
Treatment should be initiated under supervision of a physician experienced in the treatment of the disease.
Posology
Adults: The recommended dosage for the treatment of relapsing MS is 30 micrograms (0.5 ml solution), administered by intramuscular (IM) injection once a week (see section 6.6). No additional benefit has been shown by administering a higher dose (60 micrograms) once a week.
Titration: To help patients reduce the incidence and severity of flu-like symptoms (see section 4.8), titration can be performed at the initiation of treatment. Titration using the pre-filled syringe can be achieved by initiating therapy on ¼ dose increments per week reaching the full dose (30 micrograms/week) by the fourth week.
An alternative titration schedule can be achieved by initiating therapy on approximately a ½ dose of AVONEX once a week before increasing to the full dose. In order to obtain adequate efficacy, a dose of 30 micrograms once a week should be reached and maintained after the initial titration period.
The AVOSTARTCLIP titration kit is designed for use with the pre-filled syringe only. It can be used to achieve the ¼ or ½ dose increments. Each AVOSTARTCLIP should be used once and then discarded along with any remaining AVONEX in the syringe.
Prior to injection and for an additional 24 hours after each injection, an antipyretic analgesic is advised to decrease flu‑like symptoms associated with AVONEX administration. These symptoms are usually present during the first few months of treatment.
Paediatric population:
The safety and efficacy of AVONEX in children and adolescents aged 10 to 18 years have not yet been fully established. Currently available data are described in section 4.8 and 5.1 but no recommendation on a posology can be made.
The safety and efficacy of AVONEX in children below 10 years of age have not yet been established.
No data are available.
Elderly: Clinical studies did not include a sufficient number of patients aged 65 and over to determine whether they respond differently than younger patients. However, based on the mode of clearance of the active substance there are no theoretical reasons for any requirement for dose adjustments in the elderly.
Method of administration
The intramuscular injection site should be varied each week (see section 5.3).
Doctors may prescribe a 25 mm, 25 gauge needle to patients for whom such a needle is appropriate to administer an intramuscular injection.
At the present time, it is not known for how long patients should be treated. Patients should be clinically evaluated after two years of treatment and longer‑term treatment should be decided on an individual basis by the treating physician. Treatment should be discontinued if the patient develops chronic progressive MS.
- Patients with a history of hypersensitivity to natural or recombinant interferon beta or to any excipients listed in section 6.1.
- Patients with current severe depression and/or suicidal ideation (see sections 4.4 and 4.8).
Traceability
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
AVONEX should be administered with caution to patients with previous or current depressive disorders, in particular to those with antecedents of suicidal ideation (see section 4.3). Depression and suicidal ideation are known to occur in increased frequency in the multiple sclerosis population and in association with interferon use. Patients should be advised to immediately report any symptoms of depression and/or suicidal ideation to their prescribing physician.
Patients exhibiting depression should be monitored closely during therapy and treated appropriately. Cessation of therapy with AVONEX should be considered (see also sections 4.3 and 4.8).
AVONEX should be administered with caution to patients with a history of seizures, to those receiving treatment with anti-epileptics, particularly if their epilepsy is not adequately controlled with anti-epileptics (see sections 4.5 and 4.8).
Caution should be used and close monitoring considered when administering AVONEX to patients with severe renal and hepatic failure and to patients with severe myelosuppression.
Thrombotic microangiopathy (TMA): Cases of thrombotic microangiopathy, manifested as thrombotic thrombocytopenic purpura (TTP) or haemolytic uraemic syndrome (HUS), including fatal cases, have been reported with interferon beta products. Events were reported at various time points during treatment and may occur several weeks to several years after starting treatment with interferon beta. Early clinical features include thrombocytopenia, new onset hypertension, fever, central nervous system symptoms (e.g. confusion, paresis) and impaired renal function. Laboratory findings suggestive of TMA include decreased platelet counts, increased serum lactate dehydrogenase (LDH) due to haemolysis and schistocytes (erythrocyte fragmentation) on a blood film. Therefore if clinical features of TMA are observed, further testing of blood platelet levels, serum LDH, blood films and renal function is recommended. If TMA is diagnosed, prompt treatment is required (considering plasma exchange) and immediate discontinuation of AVONEX is recommended.
Nephrotic Syndrome: Cases of nephrotic syndrome with different underlying nephropathies including collapsing focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), membranoproliferative glomerulonephritis (MPGN) and membranous glomerulopathy (MGN) have been reported during treatment with interferon-beta products. Events were reported at various time points during treatment and may occur after several years of treatment with interferon beta. Periodic monitoring of early signs or symptoms, e.g. oedema, proteinuria and impaired renal function is recommended, especially in patients at higher risk of renal disease. Prompt treatment of nephrotic syndrome is required and discontinuation of treatment with AVONEX should be considered.
Hepatic injury including elevated serum hepatic enzyme levels, hepatitis, autoimmune hepatitis and hepatic failure has been reported with interferon beta in post-marketing (see section 4.8). In some cases, these reactions have occurred in the presence of other medicinal products that have been associated with hepatic injury. The potential of additive effects from multiple medicinal products or other hepatotoxic agents (e.g. alcohol) has not been determined. Patients should be monitored for signs of hepatic injury and caution exercised when interferons are used concomitantly with other medicinal products associated with hepatic injury.
Patients with cardiac disease, such as angina, congestive heart failure or arrhythmia, should be closely monitored for worsening of their clinical condition during treatment with AVONEX. Flu‑like symptoms associated with AVONEX therapy may prove stressful to patients with underlying cardiac conditions.
Laboratory abnormalities are associated with the use of interferons. Therefore, in addition to those laboratory tests normally required for monitoring patients with MS, complete and differential white blood cell counts, platelet counts, and blood chemistry, including liver function tests, are recommended during AVONEX therapy. Patients with myelosuppression may require more intensive monitoring of complete blood cell counts, with differential and platelet counts.
Patients may develop antibodies to AVONEX. The antibodies of some of those patients reduce the activity of interferon beta‑1a in vitro (neutralising antibodies). Neutralising antibodies are associated with a reduction in the in vivo biological effects of AVONEX and may potentially be associated with a reduction of clinical efficacy. It is estimated that the plateau for the incidence of neutralising antibody formation is reached after 12 months of treatment. Recent clinical studies with patients treated up to three years with AVONEX suggest that approximately 5% to 8% develop neutralising antibodies.
The use of various assays to detect serum antibodies to interferons limits the ability to compare antigenicity among different products.
In post marketing experience, cases of injection site necrosis have been reported (see section 4.8). To minimise the risk of injection site reactions, patients should be advised to use an aseptic injection technique and rotate the injection sites with each dose.
The procedure for the self-administration by the patient should be reviewed periodically especially if injection site reactions have occurred. If the patient experiences any break in the skin, which may be accompanied by swelling or drainage of fluid from the injection site, the patient should be advised to speak with their doctor. Whether to discontinue therapy following a single site of necrosis is dependent on the extent of necrosis. For patients who continue therapy with AVONEX after injection site necrosis has occurred, avoid administration of AVONEX into the affected area until it is fully healed. If multiple lesions occur, change injection site, or discontinue therapy until healing occurs.
No formal interaction studies have been performed in humans.
The interaction of AVONEX with corticosteroids or adrenocorticotropic hormone (ACTH) has not been studied systematically. The clinical studies indicate that MS patients can receive AVONEX and corticosteroids or ACTH during relapses.
Interferons have been reported to reduce the activity of hepatic cytochrome P450‑dependent enzymes in humans and animals. The effect of high-dose AVONEX administration on P450‑dependent metabolism in monkeys was evaluated and no changes in liver metabolising capabilities were observed. Caution should be exercised when AVONEX is administered in combination with medicinal products that have a narrow therapeutic index and are largely dependent on the hepatic cytochrome P450 system for clearance, e.g. some classes of antiepileptics and antidepressants.
Pregnancy
A large amount of data (more than 1000 pregnancy outcomes) from registries and post-marketing experience indicates no increased risk of major congenital anomalies after pre-conception exposure to interferon beta or such exposure during the first trimester of pregnancy. However, the duration of exposure during the first trimester is uncertain, because data were collected when interferon beta use was contraindicated during pregnancy, and treatment likely interrupted when pregnancy was detected and/or confirmed. Experience with exposure during the second and third trimester is very limited.
Based on animal data (see section 5.3), there is a possibly increased risk for spontaneous abortion. The risk of spontaneous abortions in pregnant women exposed to interferon beta cannot adequately be evaluated based on the currently available data, but the data do not suggest an increased risk so far.
If clinically needed, the use of Avonex may be considered during pregnancy.
Breast-feeding
Limited information available on the transfer of interferon beta-1a into breast milk, together with the chemical / physiological characteristics of interferon beta, suggests that levels of interferon beta-1a excreted in human milk are negligible. No harmful effects on the breastfed newborn/infant are anticipated.
Avonex can be used during breast-feeding.
Fertility
Fertility and developmental studies in rhesus monkeys have been carried out with a related form of interferon beta 1a. At very high doses, anovulatory and abortifacient effects in test animals were observed (see section 5.3).
No information is available on the effects of interferon beta-1a on male fertility.
No studies on the effects of AVONEX on the ability to drive and use machines have been performed. Central nervous system‑related adverse reactions may have a minor influence on the ability to drive and use machines in susceptible patients (see section 4.8).
The highest incidence of adverse reactions associated with AVONEX therapy is related to flu‑like symptoms. The most commonly reported flu‑like symptoms are myalgia, fever, chills, sweating, asthenia, headache and nausea. Titrating AVONEX at the initiation of therapy has demonstrated a reduction in the severity and incidence of flu-like symptoms. Flu‑like symptoms tend to be most prominent at the initiation of therapy and decrease in frequency with continued treatment.
Transient neurological symptoms that may mimic MS exacerbations may occur following injections. Transient episodes of hypertonia and/or severe muscular weakness that prevent voluntary movements may occur at any time during treatment. These episodes are of limited duration, temporally related to the injections and may recur after subsequent injections. In some cases these symptoms are associated with flu‑like symptoms.
The frequencies of adverse reactions are expressed in patient‑years, according to the following categories:
Very common (≥1/10 patient‑years);
Common (≥1/100 to <1/10 patient‑years);
Uncommon (≥1/1, 000 to <1/100 patient‑years);
Rare (≥1/10, 000 to <1/1,000 patient‑years);
Very rare (<1/10,000 patient‑years);
Not known (cannot be estimated from the available data).
Patient‑time is the sum of individual units of time that the patient in the study has been exposed to AVONEX before experiencing the adverse reaction. For example, 100 person‑years could be observed in 100 patients who were on treatment for one year or in 200 patients who were on treatment for half a year.
Adverse reactions identified from studies (clinical trials and observational studies, with a period of follow‑up ranging from two years to six years) and other adverse reactions identified through spontaneous reporting from the market, with unknown frequency, are provided in the table below.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Investigations
common
uncommon
not known
lymphocyte count decreased, white blood cell count decreased, neutrophil count decreased, hematocrit decreased, blood potassium increased, blood urea nitrogen increased
platelet count decreased
weight decreased, weight increased, liver function tests abnormal
Cardiac disorders
not known
cardiomyopathy, congestive heart failure (see section 4.4), palpitations, arrhythmia, tachycardia
Blood and lymphatic system disorders
not known
rare
pancytopenia, thrombocytopenia
thrombotic microangiopathy including thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome*
Nervous system disorders
very common
common
not known
headache2
muscle spasticity, hypoesthesia
neurological symptoms, syncope3, hypertonia, dizziness, paraesthesia, seizures, migraine
Respiratory, thoracic and mediastinal disorders
common
rare
not known
rhinorrhoea
dyspnoea
pulmonary arterial hypertension┼
Gastrointestinal disorders
common
vomiting, diarrhoea, nausea2
Skin and subcutaneous tissue disorders
common
uncommon
not known
rash, sweating increased, contusion
alopecia
angioneurotic oedema, pruritus, rash vesicular, urticaria, aggravation of psoriasis
Musculoskeletal and connective tissue disorders
common
not known
muscle cramp, neck pain, myalgia2, arthralgia, pain in extremity, back pain, muscle stiffness, musculoskeletal stiffness
systemic lupus erythematosus, muscle weakness, arthritis
Renal and urinary disorders
rare
nephrotic syndrome, glomerulosclerosis (see section 4.4 'special warnings and precautions')
Endocrine disorders
not known
hypothyroidism, hyperthyroidism
Metabolism and nutrition disorders
common
anorexia
Infections and infestations
not known
injection site abscess1
Vascular disorders
common
not known
flushing
vasodilatation
General disorders and administration site conditions
very common
common
uncommon
not known
flu‑like symptoms, pyrexia2, chills2, sweating2
injection site pain, injection site erythema, injection site bruising, asthenia2, pain, fatigue2, malaise, night sweats
injection site burning
injection site reaction, injection site inflammation, injection site cellulitis1, injection site necrosis, injection site bleeding, chest pain
Immune system disorders
not known
anaphylactic reaction, anaphylactic shock, hypersensitivity reactions (angioedema, dyspnoea, urticaria, rash, pruritic rash)
Hepatobiliary disorders
not known
hepatic failure (see section 4.4), hepatitis, autoimmune hepatitis
Reproductive system and breast disorders
uncommon
metrorrhagia, menorrhagia
Psychiatric disorders
common
not known
depression (see section 4.4), insomnia
suicide, psychosis, anxiety, confusion, emotional lability
*Class label for interferon beta products (see section 4.4).
┼ Class label for interferon products, see below Pulmonary arterial hypertension.
1Injection site reactions including pain, inflammation and very rare cases of abscess or cellulitis that may require surgical intervention have been reported.
2The frequency of occurrence is higher at the beginning of treatment.
3A syncope episode may occur after AVONEX injection, it is normally a single episode that usually appears at the beginning of the treatment and does not recur with subsequent injections.
Pulmonary arterial hypertension
Cases of pulmonary arterial hypertension (PAH) have been reported with interferon beta products. Events were reported at various time points including up to several years after starting treatment with interferon beta.
Paediatric population
Limited data from literature, clinical trials and postmarketing experience suggest that the safety profile in children and adolescents from 10 to less than 18 years of age receiving AVONEX 30 micrograms IM once per week is consistent with that seen in adults.
The safety information obtained from the use of AVONEX as an active comparator in a 96 week open label, randomised trial in paediatric patients with relapsing remitting multiple sclerosis aged 10 to less than 18 years (with only 10% of the overall study population < 13 years) shows that in the AVONEX group (n=72), the following adverse events which are common in adult population were reported as very common in paediatric population: myalgia, pain in extremity, fatigue, and arthralgia.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme.
Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
No case of overdose has been reported. However, in case of overdose, patients should be hospitalised for observation and appropriate supportive treatment given.
Ask anything about AVONEX 30 micrograms/0.5 ml solution for injection. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.